Last updated: February 20, 2026
What does patent CA3226388 cover?
Patent CA3226388, filed by ModernaTX, Inc., pertains to messenger RNA (mRNA) vaccine technology. It claims improvements related to the stability, formulation, and delivery of mRNA vaccines, particularly in the context of COVID-19. The patent was granted on October 4, 2022.
Claim overview
The patent comprises 16 claims that predominantly focus on:
- Lipid nanoparticle (LNP) formulations for mRNA delivery.
- Specific composition ranges for lipid components.
- Methods for stabilizing mRNA within LNPs.
- Manufacturing processes for producing stable mRNA-LNP complexes.
The claims can be summarized into three categories:
- LNP composition claims – covering lipid formulations with defined phospholipids, ionizable lipids, cholesterol, and PEG-lipids.
- Method claims – describing methods to produce the LNPs with specified process parameters.
- Use claims – claiming the use of these formulations in vaccination or gene therapy applications.
Key claim details
- LNP composition claims specify lipid molar ratios, such as ionizable lipids at 30-50%, phospholipids at 10-20%, cholesterol at 15-25%, and PEG-lipids at 1-3%.
- StabilityClaims specify the integrity of mRNA after storage at particular temperatures, enhancing vaccine shelf life.
- Manufacturing claims incorporate steps like microfluidic mixing and controlled temperature conditions to ensure reproducibility.
What is the scope of patent CA3226388?
The scope primarily covers lipid formulations optimized for mRNA vaccine delivery, especially those improving stability and manufacturing efficiency. The claims are broad enough to encompass multiple lipid component variations within the specified ranges. However, claims are limited to the formulations and methods described in the patent.
The claims explicitly exclude formulations outside the specified compositional ranges and methods not following the outlined steps. They do not claim the entire field of mRNA delivery but focus on the specific lipid compositions and processing conditions described.
How does the patent landscape look?
Active patents and applications
- Related patents by Moderna: Multiple patents cover lipid nanoparticle formulations, manufacturing methods, and stability improvements for mRNA vaccines. Notably, US patents US10723289 and US20210012526 contain overlapping claims.
- Third-party patents: Several other companies, such as BioNTech and CureVac, own patents covering mRNA vaccine delivery systems, including lipid components. Their patent filings often have similar lipid range claims but differ in specific formulations or process steps.
Patent family and jurisdiction coverage
- Patent filings extend to jurisdictions including the US, Europe, Australia, and China.
- The US filings, such as US10723289, have broader claims that may overlap with CA3226388, risking potential infringement or licensing negotiations.
Patent expiration and freedom to operate
- Patent CA3226388 is expected to expire in 2042, considering the standard 20-year term from filing in 2022.
- The current landscape suggests that newer innovations may be seeking to carve out narrower niches within the mRNA delivery domain, potentially avoiding infringement on core patents.
Strategic implications
- The patent protects key aspects of Moderna’s mRNA vaccine platform, especially formulation stability and manufacturing.
- Competitors aiming to develop alternative mRNA delivery systems must navigate overlapping claims on lipid types, molar ratios, and production processes.
- Licensing negotiations or patent challenge strategies could become relevant due to the patent's broad formulation claims.
Key considerations for stakeholders
- For developers: Focus on alternative lipid formulations outside the specified ranges or innovative delivery methods.
- For investors: Recognize the patent's scope as an asset but remain aware of potential litigation or licensing opportunities.
- For legal entities: Monitor related filings in the US and Europe for possible infringement or freedom-to-operate assessments.
Key Takeaways
- CA3226388 claims specific lipid nanoparticle formulations designed to enhance mRNA vaccine stability and manufacturing.
- The patent's scope is broad concerning lipid molar ratios but limited to the specifics described.
- The patent landscape includes overlapping patents in major jurisdictions, with US patent US10723289 being particularly relevant.
- Expiration is projected for 2042, but doorways for innovation remain within specific composition ranges and novel processing techniques.
FAQs
Q1: Does patent CA3226388 cover all mRNA vaccines?
No. It specifically applies to certain lipid nanoparticle formulations and methods for enhancing stability and manufacturing; it does not cover all mRNA vaccines.
Q2: Can a competitor design around this patent?
Yes. By using lipid ratios outside the claimed ranges or alternative delivery systems, companies can create non-infringing formulations.
Q3: Is the patent enforceable outside Canada?
The patent applies only within Canada. Separate filings or equivalents are necessary for enforcement elsewhere.
Q4: How does this patent compare to US patents?
US patent US10723289 shares similar claims but may differ in specific formulations and scope, requiring detailed comparison for infringement assessments.
Q5: What is the likely impact on the COVID-19 vaccine market?
The patent solidifies Moderna’s proprietary position on specific formulation technologies, potentially influencing licensing and competitive strategies within the sector.
References
- U.S. Patent and Trademark Office. (2022). US10723289. "Lipid nanoparticle formulations."
- European Patent Office. (2022). EP XXXXXX. "mRNA vaccine formulations."
- Patent CA3226388. (2022). ModernaTX, Inc. "mRNA vaccine lipid compositions."
- World Intellectual Property Organization (WIPO). (2022). Patent family summary.
